Email:
global@GCP-ClinPlus.com
We are pleased to announce that the long-acting GLP-1 therapy Visepegenatide Injection has received marketing approval from the NMPA on November 14, 2025! As the clinical research partner of PegBio, GCP ClinPlus supported the Phase I through III clinical programs, contributing to this significant advancement in metabolic disease treatment.
Integrated Clinical Excellence Across All Stages
Our team delivered end-to-end services encompassing site management, medical monitoring, data management, and biostatistics. The high-quality data from the study also supported publication of the results in The Lancet, underscoring its scientific rigor.
Deep Expertise in Metabolic Diseases
As a council member of the China Endocrinology & Metabolism Collaboration Network, we leveraged leading endocrine research centers and our in-house endocrinology specialists to ensure efficient trial execution and outstanding quality.
With 22 years of experience and over 2,200 clinical projects completed, GCP ClinPlus is honored to have helped advance this innovative GLP-1 therapy from clinical development to regulatory approval.
Congratulations to PegBio and all teams involved!
Contact us: global@gcp-clinplus.com